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AbstrACt
background Elimination of cancer cells by some 
stimuli like chemotherapy and radiotherapy activates 
anticancer immunity after the generation of damage‐
associated molecular patterns, a process recently named 
immunogenic cell death (ICD). Despite the recent advances 
in cancer immunotherapy, very little is known about the 
immunological consequences of cell death activated 
by cytotoxic CD8+ T (Tc) cells on cancer cells, that is, if 
Tc cells induce ICD on cancer cells and the molecular 
mechanisms involved.
Methods ICD induced by Tc cells on EL4 cells was analyzed 
in tumor by vaccinating mice with EL4 cells killed in vitro or 
in vivo by Ag- specific Tc cells. EL4 cells and mutants thereof 
overexpressing Bcl- X
L or a dominant negative mutant of 
caspase-3 and wild- type mice, as well as mice depleted of 
Tc cells and mice deficient in perforin, TLR4 and BATF3 were 
used. Ex vivo cytotoxicity of spleen cells from immunized 
mice was analyzed by flow cytometry. Expression of ICD 
signals (calreticulin, HMGB1 and interleukin (IL)-1β) was 
analyzed by flow cytometry and ELISA.
results Mice immunized with EL4.gp33 cells killed in 
vitro or in vivo by gp33- specific Tc cells were protected 
from parental EL4 tumor development. This result was 
confirmed in vivo by using ovalbumin (OVA) as another 
surrogate antigen. Perforin and TLR4 and BATF3- 
dependent type 1 conventional dendritic cells (cDC1s) 
were required for protection against tumor development, 
indicating cross- priming of Tc cells against endogenous 
EL4 tumor antigens. Tc cells induced ICD signals in 
EL4 cells. Notably, ICD of EL4 cells was dependent on 
caspase-3 activity, with reduced antitumor immunity 
generated by caspase-3–deficient EL4 cells. In contrast, 
overexpression of Bcl- X
L in EL4 cells had no effect on 
induction of Tc cell antitumor response and protection.
Conclusions Elimination of tumor cells by Ag- specific 
Tc cells is immunogenic and protects against tumor 
development by generating new Tc cells against EL4 
endogenous antigens. This finding helps to explain the 
enhanced efficacy of T cell- dependent immunotherapy and 
provide a molecular basis to explain the epitope spread 
phenomenon observed during vaccination and chimeric 
antigen receptor (CAR)- T cell therapy. In addition, they 
suggest that caspase-3 activity in the tumor may be used 
as a biomarker to predict cancer recurrence during T cell- 
dependent immunotherapies.
bACkground
In the past few years, a major understanding 
of the regulation of cancer immunity has 
allowed to develop new immunotherapy 
approaches that have shown unprecedented 
efficacy against aggressive bad prognosis 
cancers.1 2 Natural killer (NK) cells and cyto-
toxic CD8+ T (Tc) cells are the key respon-
sible for the elimination of transformed cells 
during both cancer immunosurveillance and 
immunotherapy.3–6 However, meanwhile NK 
cells eliminate stressed tumor cells and/or 
cells that have downregulated major histo-
compatibilty complex (MHC)- I molecules,7 
activation of Tc cells strictly depends on the 
recognition of antigens presented by MHC- I. 
Thus, the presence of tumor- mutated genes 
raising new epitopes/antigens (neoantigens) 
together with proper inflammatory signals 
leading to efficient antigen cross- presentation 
by dendritic cells (DCs) are prerequisites 
for the generation of an effective Tc cell- 
mediated anticancer response.8 Accordingly, 
response to immunotherapy treatments that 
rely on T cell immunity, such as checkpoint 
antibody therapy, is limited to cancers that 
express immunodominant mutations that 
raise an optimal T cell response.
As an alternative to overcome this limita-
tion, in recent years, it has been described 
that specific chemotherapy drugs and irra-
diation, in addition to kill cancer cells, have 
the capacity to prime anticancer immune 
responses against antigens released from 
dying cells, a concept known as immuno-
genic cell death (ICD).9–11 This process 
enhances the elimination of cancer cells 
and generates immune memory against the 
tumor antigens, reducing the chance of 
cancer recurrence.10 12 This ability is related 
to the activation of danger signaling path-
ways evoking emission of damage- 
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molecular patterns (DAMPs) leading to inflamma-
tion, which favor DC maturation and antigen presenta-
tion.10 13–15 ICD increases the immunogenicity of tumor 
antigens that per se might present a lower antigenic poten-
tial and would not induce an efficient T cell response. In 
recent years, some molecular determinants that dictate 
the immunogenic characteristics of dying cells have been 
clarified.16 Apoptosis, ferroptosis, pyroptosis or necro-
ptosis are among the different modalities of programmed 
cell death that can be immunogenic.17–20
Several molecules involved in the generation of eat- me 
and danger signals leading to ICD in cancer cells have 
been found such as exposure of calreticulin on the cell 
membrane, release of Hsp70 or HMGB1, autophagy and 
production of interleukin (IL)-1β or type I interferon 
(IFN).16 At present, the relative importance of each of 
these signals is not clear and different ICD signals have 
been described in cells dying under different stimuli. 
Thus, to find out if cancer cells eliminated by a specific 
stimulus undergo ICD, the generation of anticancer 
immunity and tumor development should be analyzed in 
vivo in animals previously immunized with dead cancer 
cells.
Despite the extensive studies focused on the mecha-
nisms involved in tumor cell recognition by T cells, the 
molecular determinants that regulate cell death induced 
by Tc cells on cancer cells, a key event for successful cancer 
immunotherapy, are less characterized. Paradoxically, 
little is known about the immunogenic characteristics 
of cancer cell death induced by immunotherapy. Specif-
ically, whether cell death induced by Tc cells is immuno-
genic and, if so, which are the mechanisms responsible 
for ICD induced by Tc cells?
Tc cells mainly use two pathways to kill cancer cells, 
death ligands (ie, tumor necrosis factor (TNF)-α, fas 
ligand and TNF- related apoptosis inducing ligand 
(TRAIL)) or granule exocytosis.21 22 The later consists 
of the release of a pore- forming protein perforin (perf) 
that delivers a family of serine- proteases, the granzymes 
(gzms) into the cytosol of target cells. Gzms are the ulti-
mate responsible (mainly gzmB) for cancer cell elimina-
tion. Apart from regulating target cell death, it was shown 
that gzms are involved in antigen cross- presentation of 
dying cells by somehow regulating DC phagocytosis.23 In 
a recent work, we have shown that Tc cells efficiently elim-
inate in vivo tumor cells expressing pro- tumorigenic and/
or anti- apoptotic mutations.24 These results provided 
the molecular basis to explain the efficacy of immuno-
therapy against multidrug- resistant bad prognosis cancer. 
However, these findings raise a new question to predict 
refractoriness and/or cancer relapse after immuno-
therapy: is Tc cell mediated- elimination of cancer cells 
immunogenic? And if so, what is the impact of mutations 
in cell death/prosurvival pathways on the immunoge-
nicity of cancer cell death induced by Tc cells?
Here we have employed the EL4 lymphoma mouse 
model and different cancer vaccination strategies based 
on the gp33 and OVA tumor Ag models to explore the 
immunogenic characteristics of cell death induced by Tc 
cells on cancer cells and the mechanisms involved in this 
process both in vitro and in vivo. Our results show that 
T cell cytotoxic activity on tumor cells induces ICD and 
promotes a protective immune response in vivo, priming 
the generation of new CD8+ Tc cell responses against 
endogenous tumor antigens. Importantly, this response 
is able to reduce tumor development in mice challenged 
with a second tumor. Additionally, our results show that 




Inbred C57BL/6 (B6) and mouse strains deficient for 
perf (perfKO) and TLR4 (TLR4KO), bred on the B6 back-
ground, were maintained at the Center for Biomedical 
Research of Aragon (CIBA) and analyzed for their geno-
types as described.25 Mouse strains deficient for BATF3 
(BATF3KO) on the C57BL/6 background were kindly 
given by Dr David Sancho (Research Center for Cardio-
vascular Diseases Carlos III, Madrid, Spain). Mice from 
both sexes and 8–10 weeks of age were used.
Cell lines, cell culture and reagents
EL4, EL4.DNC3 and EL4.Bcl- XL cells were cultured in 
Roswell Park Memorial Institute (RPMI) medium with 
5% heat- inactivated FBS at 37°C. EL4 cells overexpressing 
Bcl- XL or expressing a dominant negative mutant of 
caspase-3 (Cys285Ala; DNC3; Genscript)26 were gener-
ated by lentiviral infection employing the pBABE- puro 
vector containing the cDNA of the proteins and the 
psPAX and pMD2.G vectors containing the HIV-1 Gag 
and Pol and VSV Env proteins, respectively. Transfected 
cell clones were selected by limiting dilution, employing 
conditioned medium and puromycin as antibiotic of 
selection.
Mouse vaccination and isolation of ex vivo Cd8+tc cells
Mice were immunized with LCMV- WE intraperitoneal 
(105 pfu) in 200 μL of RPMI 2% heat- inactivated FBS. On 
day 8 postinfection, CD8+ cells were positively selected 
from spleen using α-CD8- MicroBeads (Miltenyi Biotec, 
Germany) and a MACS- cell separation system and resus-
pended in RPMI 5% heat- inactivated FBS before use in 
cytotoxic assays. Purity of selected CD8+ cells was assessed 
by fluorescence- activated cell sorting (FACS) staining and 
found to be between 95% and 98%.
ex vivo cytotoxicity assays
Target cells were preincubated with the LCMV- derived 
peptide gp33 (Neosystem Laboratoire) and MACS- 
enriched ex vivo virus immune CD8+ T cells were stained 
with CellTracker Green (CTG; Invitrogen). Effector 
and target cells were incubated at different ratios 
depending on the conditions (10:1, 7:1, 3:1, 1:1 (effec-
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immune splenocytes from immunized mice were incu-
bated with fluorescently labeled target cells at 100:1 
ratio. Subsequently, phosphatidyl serine (PS) exposure 
on plasma membrane (Annexin V staining) and incor-
poration of 7- AAD were measured by three- color flow 
cytometry in the target population with a FACSCalibur 
(BD Pharmingen) and CellQuests software described 
previously.27
IL-1β release in cell culture supernatants was quanti-
fied using a Ready- SET- Go ELISA Set from eBioscience. 
HMGB1 release in cell culture supernatants was quanti-
fied using a kit from Finetest Biotechnolgy. Calreticulin 
exposure on plasma membrane was measured by flow 
cytometry using a specific antibody anti- mouse calretic-
ulin from Abcam (clon EPR3924, PE).
generation of mouse bone marrow–derived dendritic cells
DCs were generated from bone marrow cells using 
wild- type (wt) C57BL/6 mice, in RPMI 1640 medium 
containing 10% of FCS serum, 100 U/mL of penicillin/
streptomycin, 50 mM of 2- ME and 10% of supernatant 
of X63Ag8653 cell cultures as source of GM- CSF (Zal et 
al, 1994) (DC medium). Cells were cultured on 100 mm 
petri dishes (1×106 cells/10 mL DC culture medium). On 
days 3 and 5, the cell medium was refreshed. On day 7, 
supernatants contained cells, which showed differenti-
ated morphology and expressed the DC markers CD11c+, 
MHC- II low and CD40 low, confirming their identity as 
immature DCs. For their maturation, these DCs were 
incubated with LPS 1 μg/mL for 20 hours.
tumor development
Non- pulsed or gp33- pulsed EL4 cells were inoculated 
intraperitoneally or subcutaneously in mice following the 
different protocols described. For pulsed cells, EL4 cells 
were incubated with 100 nM gp33 or 1 μM OVA peptide 
for 1 hour at 37°C and washed before inoculation. In 
some experiments, mice were injected with 100 μg of anti- 
CD8β mAb (clon H35-17.2) or the same amount of rat 
isotype control before injecting tumor cells.
Subcutaneous tumor development was analyzed by 
measuring tumor volumes every second day. Volume 
was calculated using the equation formula W x L x H, 
where W, L and H represent the width, length and height 
of the tumor. Mice were sacrificed when they reach the 
humane endpoint as established by the Animal Ethics 
Committee (volume larger than 0.5 cm3 or presenting 
signs of ulceration).
statistical analysis
Statistical analysis was performed using GraphPad Prism 
software. The difference between means of unpaired 
samples was performed using two- way analysis of variance 
(ANOVA) with Bonferroni’s post- test or using unpaired 
t- test as indicated. Survival curves were compared using 
log- rank test (Mantel- Cox). The results are given as the CI 
with p values and are considered significant when p<0.05.
results
el4 cells killed by Ag-specific Cd8+ tc cells express ICd 
signals
We have previously shown that Ag- specific CD8+ cytotoxic 
T cells (CD8+ Tc cells) eliminate EL4 lymphoma cells in 
vitro and in vivo, independently of the apoptotic mito-
chondrial pathway, caspases, necroptosis and pyroptosis 
by a mechanism involving granule exocytosis.24 This was 
demonstrated using different cell lines expressing anti- 
apoptotic mutations. Thus, we now aimed to analyze if the 
target cells killed in vitro by CD8+ Tc cells express some of 
the molecular immunogenic determinants and the effect 
of the cell death mutations indicated above. To this aim, 
we focused on some danger signals previously described 
to participate in ICD induced by other anticancer treat-
ments like chemotherapy and radiotherapy: calreticulin 
membrane exposure (CRT) and IL-1β and HMGB1 
release.28–30 CRT is an ‘eat- me’ signal that contributes 
to the uptake of dying cells by DCs. The nuclear protein 
HMGB1 is released when nuclear membrane is disrupted, 
acting as a danger signal. IL-1β is a well- known inflamma-
tory cytokine.
As shown in figure 1A, and confirming previous find-
ings,24 ex vivo gp33- specific Tc cells induced the same 
level of cell death in parental EL4 cells as in the EL4.
DNC3 and EL4.Bcl- XL mutant cells, being most cells 
eliminated at 3:1 effector:target ratio. A summary of the 
gating strategy shown in online supplementary figure 1. 
As previously found,24 cell death is delayed in the pres-
ence of Q- VD- OPh (figure 1A); thus, we required to 
increase effector:target ratio to 7:1 to get similar levels of 
dead cells to be used in the immunization protocols later 
on. It should be noted that at this time point (20 hours) 
all cells are positive for AAD, indicating that they have 
permeabilized plasma membrane. However, this effect 
is due to secondary necrosis observed in culture since 
at earlier time points (1–2 hours) most cells present an 
apoptotic phenotype, presenting PS translocation in 
the absence of membrane permeabilization.24Next, we 
analyzed the indicated ICD signals (figure 1B–D). In 
order to compare the results in conditions with the same 
level of cell death, a higher effector:target ratio was used 
when Q- VD was included. CRT exposure was analyzed in 
7AAD negative cells to prevent staining of intracellular 
CRT (online supplementary figure 1). CD8+ Tc killing 
dramatically increased CRT exposure in EL4.gp33 cells 
compared with EL4 control cells, and this was prevented 
if killing was performed in the presence of Q- VD or using 
target cells expressing the caspase-3 mutant, EL4DNC3.
gp33 (figure 1B). In contrast, EL4 target cells overex-
pressing Bcl- XL(EL4Bcl- XL.gp33) exposed CRT at the 
same level as EL4.gp33 cells following Tc cell killing. In 
all cases, CRT exposure was higher than the level of cell 
death (see figure 1A) and it was significantly reduced in 
the presence of QVD or in EL4DNC3 cells, even when 
cell death was not affected (see figure 1A), confirming 
that CRT exposure is not a consequence of membrane 
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Figure 1 EL4.gp33 cells killed by antigen- specific Tc cells express immunogeneic cell death signals. (A) EL4 cells and mutants 
thereof (Bcl- xL and DNC3) were incubated with ex vivo gp33- specific CD8
+ T cells from virus- immunized C57BL/6 mice in the 
presence of the gp33 Ag for 20 hours at the indicated effector:target ratios. Subsequently, phosphatydilserine exposure on 
plasma membrane and cell membrane integrity were measured by three- color flow cytometry using Annexin- V and 7- AAD as 
described in the Methods section. Data are represented as mean±SD of four independent experiments using eight mice in total. 
(B–D) EL4 cells and mutants thereof (Bcl- XL and DNC3) were incubated with ex vivo gp33- specific CD8
+ T cells from virus- 
immunized C57BL/6 mice in the presence of the gp33 Ag for 20 hours at 1:1 effector:target ratio. A higher effector:target ratio 
(3:1) was used when QVD (30 µM) was included. Non- pulsed EL4 cells incubated with Tc cells and gp33- EL4 cells alone were 
used as controls. (B) Calreticulin exposure was analyzed by flow cytometry as indicated in the Methods section. (C, D) HMGB1 
and interleukin (IL)-1β was measured in cell supernatants by ELISA. Data are represented as the mean±SD of four independent 
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HMGB1 was significantly increased in supernatant 
from EL4.gp33 cells incubated with gp33- specific Tc 
cells compared with that from EL4 cells (figure 1C). In 
addition, HMGB1 was not released from activated Tc 
cells, confirming its specific release from dying EL4.
gp33 cells. In contrast with CRT exposure, HMGB1 
release was independent of caspase-3 inhibition or 
mutation.
IL-1β in supernatant from EL4.gp33 cells incubated 
with gp33- specific Tc cells was also increased compared 
with control cells, gp33- specific Tc cells or non- pulsed 
EL4 cells incubated with gp33- specific Tc cells. IL-1β 
production was reduced by QVD, likely due to inflam-
matory caspase inhibition. In contrast, IL-1β concentra-
tion was not reduced in EL4DNC3 or EL4.Bcl- XL cells.
These results show that Ag- specific CD8+Tc cells 
induce three main hallmarks of ICD in tumor dying 
EL4 cells, CRT exposure and HMGB1 and IL-1β release 
and indicate that these signals are differentially regu-
lated by caspases and caspase-3.
Immunization with el4.gp33 cells killed by gp33-specific tc 
cells generates Cd8+ t cell-mediated protection against el4 
tumor development
Despite the ability of Tc cells to induce ICD signals in 
target cells, this finding does not imply that this process 
is able to induce anticancer immunity against dying 
cancer cells. To decipher whether elimination of cancer 
cells by Tc cells is actually immunogenic, we analyzed if 
tumor elimination by Tc cells resulted in the priming 
of the host immune system against endogenous tumor 
antigens different from those involved in the cytotoxic 
killing of the tumor by the gp-33- specific Tc cells. We set 
up a model of whole- cell tumor vaccination employing 
gp33- pulsed EL4 cells (EL4.gp33) killed by gp33- 
specific Tc cells ex vivo as indicated in figure 1A and 
subsequently used to immunize C57Bl/6 (B6) wt mice. 
This model is summarized in figure 2A. For simplicity, 
we will refer to cells killed under this protocol as EL4.
gp33TcLCMV. As control, one group was inoculated with 
phosphate- buffered saline (PBS) -and another one was 
inoculated with the same amount of activated gp33- 
specific Tc cells alone (TcLCMV group) in order to 
analyze if immunomodulatory cytokines produced by 
Tc cell might contribute to tumor immunogenicity. 
After 7 days, mice were challenged with parental EL4 
cells in the right flank, and tumor development was 
monitored. As shown in figure 2B, tumor growth was 
delayed and survival was longer in mice immunized with 
EL4.gp33TcLCMV cells, compared with control groups 
(figure 2B). In addition, we found a slight but signifi-
cant increase in CD4+ and CD8+ infiltrating T cells in 
mice immunized with EL4.gp33TcLCMV cells compared 
with PBS control (figure 2C). However, CD8+ T cells 
also increased in mice inoculated with TcLCMV cells 
alone, which were not protected from tumor devel-
opment, indicating that increased infiltration is not 
sufficient for protection. These results indicate that 
immunization with EL4.gp33TcLCMV cells generates a 
protective immune response against parental EL4 cells. 
In addition, the data indicate that the potential immu-
nomodulatory effect of activated Tc cells is not sufficient 
to provide any protection against tumor development.
To find out whether the secondary protective 
response is dependent on anti- tumoral CD8+ Tc cells 
generated against EL4 endogenous Ags, we immunized 
mice (following the protocol indicated in figure 2A) in 
which CD8+ T cells had been depleted or mice lacking 
the cytotoxic molecule perforin (perfKO). While mice 
immunized with EL4.gp33TcLCMV cells developed signifi-
cantly smaller tumors and survived significantly longer 
than control mice, perfKO mice or those lacking CD8+ 
Tc cells lost this protection (figure 1D). Similar to 
the results obtained in figure 2C, immunization with 
EL4.gp33TcLCMV cells significantly increased the % of 
CD3+/CD4+ T cells and CD3+/CD8+ T cells in wt mice 
(figure 2E). There were not significant differences 
between wt and and perfKO mice, further indicating 
that the absence of tumor protection in perfKO mice 
was not due to a reduction in the generation/infiltra-
tion of CD8+ Tc cells. In conclusion, protective response 
to EL4 secondary challenge is dependent on CD8+ T 
cell perforin- dependent killing activity against EL4 cells 
after immunization with dying EL4.gp33TcLCMV cells.
bAtF3-dependent dendritic cells and tlr4 are required for 
priming of new el4-specific Cd8+ tc
To demonstrate that new CD8+ Tc cells are primed 
against endogenous antigens expressed on EL4 cells, we 
analyzed whether blockade of Ag cross- priming affected 
protection against EL4 tumor development after vacci-
nation with EL4.gp33TcLCMV cells. BATF3- deficient 
mice, which lack cDC1s specialized in tumor Ag cross- 
presentation,31 32 and TLR4- deficient mice, which 
lack a pathway of sensing HMGB1 involved in antigen 
processing for cross- presentation,28 were immunized 
following the protocol indicated in figure 2A. Notably, 
protection to EL4 secondary challenge conferred by 
immunization with EL4.gp33TcLCMV cells was lost in 
TLR4KO and BATF3KO mice (figure 3A). This result 
suggests the priming of new CD8+ T cells against endog-
enous EL4- derived Ags by cDC1s and using a TLR4- 
dependent pathway for improved Ag cross- presentation.
Subsequently, to confirm CD8+ Tc cell cross- priming, 
we analyzed the generation of specific CD8+ Tc cells 
against EL4 endogenous Ags in wt and TLR4KO and 
BATF3KO mice. Since EL4 endogenous tumor Ags are 
not known, it is not possible to analyze the generation 
of Ag- specific CD8+ T cells by conventional multimer 
staining.
Thus, we tested ex vivo the anti- tumoral activity of 
spleen cells from control and immunized mice against 
EL4 cells. Spleen cells from wt mice immunized with 
EL4.gp33TcLCMV cells showed increased killing capacity 
of EL4 cells compared with spleen cells from non- 
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Figure 2 EL4.gp33 cells killed ex vivo by gp33- specific Tc cells generate protection against EL4 tumors. (A) EL4 cells were 
incubated with ex vivo gp33- specific CD8+ T cells from virus- immunized C57BL/6 mice in the presence of the gp33 Ag for 
20 hours at an effector:target ratio 3:1. After this time, cell cultures were collected and used to immunize C57B/L6 mice 
intraperitoneal at day 0 and day 7 (EL4.gp33TcLCMV=gp33- EL4.gp33 cells+gp33 Tc cells). In the gp33- Tc cell group (TcLCMV), 
mice were immunized with the equivalent number of gp33- specific Tc cells (1.5×106 cells). As control, mice were immunized 
with PBS. At day 14, the three groups were inoculated with 2×105 EL4 cells in the right flank. (B) Tumor development was 
monitored over 25 days as described in the Methods section. The data correspond to 10 mice from two independent 
experiments, where ***p<0001.Two- way analysis of variance (ANOVA), with Bonferroni post- test and log- rank test (Mantel- Cox) 
in the survival graph. (C) In some mice, tumors were removed and TIL composition was analyzed by flow cytometry using the 
indicated cell markers. The data correspond to five mice from two independent experiments, where *p<0,1; **p<0,01; analyzed 
by unpaired t- test. (D) The same experiment as shown in (A) was performed but employing wild- type (WT) and perfKO mice 
or mice depleted of CD8+ T cells using an anti- CD8β monoclonal antibody (days 13, 17, 21 and 25). The data correspond 
to 10 mice from two independent experiments, where ***p<0001. Two- way ANOVA, with Bonferroni post- test and log- rank 
test (Mantel- Cox) in the survival graph. (E) In some mice, tumors were removed and TIL composition was analyzed by flow 
cytometry using the indicated cell markers. The data correspond to five mice from two independent experiments, where *p<0,1; 
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Figure 3 BATF3 and TLR4 are required for the generation of cancer immunity after immunization with dead EL4 cells. (A) EL4 
cells were incubated with ex vivo gp33- specific CD8+ T cells from virus- immunized C57BL/6 mice in the presence of the gp33 
Ag for 20 hours at an effector:target ratio 3:1. After this time, cell cultures were collected and used to immunize wild- type (wt), 
TLR4KO and BATF3KO mice at day 0 and day 7. As control, mice were immunized with PBS. On day 14, mice were inoculated 
with 2×105 EL4 cells in the right flank. Tumor development was monitored over 25 days as described in the Methods section. 
The data correspond to 10 mice from two independent experiments, where ***p<0001. Two- way analysis of variance (ANOVA), 
with Bonferroni post- test and log- rank test (Mantel- Cox) in the survival graph’s. WT, TLR4KO and BATF3KO mice were immunized 
with gp33- pulsed EL4 dead cells as indicated in (A). On day 10, splenocytes from these mice were isolated and incubated at 
an effector:target ratio 100:1 with EL4 cells in the presence or absence of the viral peptide GP33. After 18 hours, PS exposure 
on plasma membrane was measured by three- color flow cytometry using Annexin- V. Data are represented as the mean±SD of 
three independent experiments using six mice in total, where *p<0,1; analyzed by unpaired t- test.
EL4.gp33TcLCMV- immunized mice deficient in TLR4 or 
BATF3 (figure 3B). These results show that BATF3 and 
TLR4- dependent cross- priming to dying EL4.gp33TcLCMV 
generates an effective Tc response to endogenous EL4 
Ags that is dependent on granule exocytosis (figure 2).
gp33-speCIFIC Cd8+tC kIllIng In vIvo Also proteCts 
AgAInst el4 seCondAry ChAllenge
To demonstrate whether Ag- specific CD8+Tc cell killing 
in vivo was immunogenic, we employed a clinical rele-
vant immunotherapy protocol consisting of vaccination 
with DCs loaded with gp33 Ag (DCgp33) (figure 4A). This 
protocol has shown good efficacy in vivo n mice using 
other antigen models.33 A summary of the protocol used 
is depicted in figure 4A. Immunization with mature 
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Figure 4 Vaccination with dendritic cells (DCs) pulsed with gp33 induces Tc cell- dependent protection against EL4.gp33 
tumors. Upper panels: C57BL/6 WT, perfKO mice or mice depleted of CD8+ T cells using an anti- CD8β monoclonal antibody 
(days 5, 9, 13 and 17) were inoculated with PBS (control) or with 2×106 mature DC alone (DC) or incubated with gp33 peptide 
(DCgp33) intraperitoneal on day 6, the three groups were inoculated with 2.5×105 gp33- EL4 cells in the right flank. Tumor 
development was monitored over 50 days as described in the Methods section. The data correspond to 12 mice from three 
independent experiments, where ***p<0.001. Two- way analysis of variance with Bonferroni post- test and log- rank test (Mantel- 
Cox).
tumor development compared with mice non- immunized 
or those immunized with DCs matured but without gp33 
(figure 4B). Protection against EL4.gp33 tumor develop-
ment was completely abrogated when CD8+ T cells were 
depleted or in perfKO mice (figure 4C). These results 
indicate that immunization with mature DCgp33 generates 
a CD8+ T cell- dependent and perf- dependent protec-
tion against EL4 tumor development, showing that this 
model is suitable to analyze immunogenicity of cell death 
induced by CD8+ Tc cells in vivo.
Next, we analyzed if the elimination of EL4.gp33 
cells in vivo in mice immunized with DCgp33 (from now 
on EL4.gp33TcDC cells) generated a protective response 
against parental EL4 tumors. Mice inoculated with 
mature DCgp33 developed EL4 tumors and reach the 
endpoint on day 15 (DCgp33, figure 5A), similar to control 
non- immunized mice (figure 3A). In contrast, EL4 tumor 
development was largely reduced and survival increased 
in mice immunized following the protocol EL4.gp33TcDC 
(figure 5A). This tumor protection was lost on CD8+ T 
cell depletion, showing that elimination of parental EL4 
cells was dependent on the generation of new CD8+ Tc 
cells specific against EL4 endogenous antigens. A similar 
result was found, when the same protocol was performed, 
but using the OVA antigen instead of gp33. In this case, 
elimination of EL4OVA cells in vivo in mice immunized 
with DCOVA generated a protective response that signifi-
cantly delayed the growth of parental EL4 tumors (online 
supplementary figure 2), indicating that immunization 
against endogenous EL4 tumors was independent of the 
antigen model.
To confirm that CD8+ Tc cells cross- primed against 
dying EL4.gp33- derived antigens were the respon-
sible of EL4 tumor elimination, we employed an adop-
tive transfer protocol using CD8+T cells from wt and 
BATF3KO mice, previously immunized following the 
protocol EL4.gp33TcDC (figure 5B). Only those mice 
transferred with CD8+ Tc cells from EL4.gp33TcDC immu-
nized wt mice showed protection against EL4 tumor 
development compared with mice transferred with Tc 
from wt mice immunized with DCgp33, or Tc coming 
from BATF3- deficient mice independently of the immu-
nization stimulus (figure 5B). These results show that 
in vivo elimination of EL4.gp33 cells by gp33 Ag- spe-
cific CD8+Tc cells is immunogenic and cross- primes a 
CD8+ Tc cell response against endogenous EL4- derived 
antigens, suggesting that is a general mechanism of 
epitope spreading not only applicable to adoptive T cell 
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Figure 5 EL4.gp33 cells killed in vivo after immunization with dendritic cells (DCs) pulsed with gp33 protects against EL4 
tumor development. (A) C57BL/6 mice were inoculated with mature gp33- DCs. On day 6, the control group was inoculated with 
PBS (control) and the rest of groups were inoculated with 2.5×105 gp33- EL4 cells in the right flank (EL4.gp33TcDC). On day 20, all 
groups were inoculated with 2×105 EL4 cells in the left flank. In one group of mice CD8 cells were depleted employing an anti- 
CD8β monoclonal antibody (days 19, 23, 27 and 31) (EL4.gp3TcDC anti- CD8). Tumor development was monitored over 50 days 
as described in theMethods section. The data correspond to 12 mice from three independent experiments, where ***p<0.001. 
Two- way analysis of variance (ANOVA) with Bonferroni post- test and log- rank test (Mantel- Cox). (B) C57BL/6 wt and BATF3KO 
mice were inoculated with 3×106 mature DCs (LPS 1 µg/mL 20 hours) incubated with gp33 peptide via intraperitoneal. On day 6, 
one group was inoculated with PBS (Tc wt DCsgp33, Tc BATF3KO DCsgp33) and the other group was inoculated with 5×105 gp33- 
EL4 cells in the right flank (TC wt EL4.gp33TcDC, Tc BATF3KO EL4.gp33TcDC). Seven days later, mice were sacrificed, CD8+ Tc cells 
from the spleen and lymph nodes were enriched by MACS and transferred (6×106 cells) into C57BL/6 wt mice, who had been 
inoculated with 1.5×105 EL4 cell. Tumor development was monitored over 20 days as described in the Methods section. The 
data correspond to five mice from one experiment, where **p<0.01; ***p<0.001. Two- way ANOVA with Bonferroni post- test and 
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role oF CAspAses And the MItoChondrIAl Cell deAth 
pAthwAy In ICd InduCed by Cd8+ tC Cells
Finally, we wondered how the mutations on cell death 
pathways analyzed in figure 1 in vitro would affect the 
immune response against tumor Ags derived from 
cancer cells eliminated by Tc cells in vivo. To this aim, we 
analyzed the role of caspases and the mitochondrial cell 
death pathway in the generation of immunity against EL4 
tumor development after vaccination. The level of protec-
tion offered by EL4.gp33 cells killed in vivo after DCgp33 
vaccination was much pronounced as compared with the 
protocol employing EL4.gp33 killed in vitro (figures 5 
and 2). However, in order to reduce the number or mice 
and to study the mechanism in a more controlled way, 
we followed the vaccination protocol with EL4.gp33 
killed in vitro (EL4.gp33TcLCMV cells), using EL4.gp33 
wt cells as well as mutants thereof overexpressing Bcl- 
XL or expressing a dominant negative caspase-3 mutant 
(DNC3). In addition, we used EL4.gp33 wt cells in which 
caspases were blocked with the pan- inhibitor Q- VD- OPh.
Mice were immunized employing the cells killed in 
figure 1A, following the protocol indicated previously 
(figure 2). As shown in figure 6A, mice immunized 
with EL4.gp33TcLCMV cells were protected against tumor 
development and survived significantly longer than non- 
immunized control mice. In contrast, protection disap-
peared in those mice immunized with EL4.gp33TcLCMV 
cells that had been killed in the presence of Q- VD, indi-
cating that functional caspases are required to generate 
protection against parental EL4 tumor development. A 
similar result was found when EL4DNC3.gp33TcLCMV cells 
were used. The protection observed after immunization 
with EL4.gp33TcLCMV was lost when cells expressed the 
caspase-3 mutant (EL4DNC3.gp33TcLCMV, figure 6B). In 
contrast, mice immunized with EL4Bcl- XL.gp33
TcLCMV 
cells were protected and developed EL4 tumors signifi-
cantly smaller and survived significantly longer than non- 
immunized control mice (figure 6B). Although tumors 
were slightly bigger than mice immunized with EL4.
gp33TcLCMV, neither tumor growth nor mouse survival was 
significantly different. Therefore, this result suggests that 
the intrinsic apoptotic pathway is dispensable for CD8+ 
Tc- induced ICD in EL4 tumor model, which critically 
depends on the presence of active caspase-3.
To confirm the role of caspase-3 in ICD induced by 
CD8+Tc cells, we analyzed the generation of EL4- specific 
CD8+ Tc cells after immunization with EL4.gp33 dead 
cells. Splenocytes from mice immunized with EL4.
gp33TcLCMV showed increased killing of parental EL4 
cells in vitro compared with splenocytes from control 
mice or those immunized with EL4.gp33TcLCMV killed in 
the presence of Q- VD or with EL4DNC3.gp33TcLCMV cells 
(figure 6C). Cytotoxic activity of splenocytes from mice 
immunized with EL4Bcl- XL.gp33
TcLCMV cells was similar to 
that from EL4.gp33TcLCMV immunized mice. These results 
confirm that caspase-3, but not the intrinsic apoptotic 
pathway, is required for ICD induced by CD8+ Tc cells, 
including the generation of a protective anti- tumor CD8+ 
Tc cell response.
dIsCussIon
A major understanding of the regulation of CD8+ Tc cell- 
mediated immunity in cancer has been key to successfully 
treat mutated bad prognosis cancers with immune check-
point inhibitors or with modified CAR- T cells. However, 
the number of patients benefiting from immunotherapy 
is still relatively low and restricted to a small propor-
tion of some types of cancer. The factors contributing 
to immunotherapy efficacy and tumor resistance and/
or relapse are poorly explored. We have recently shown 
that antigen- specific Tc cells are able to eliminate tumor 
cells expressing anti- apoptotic mutations conferring bad 
prognosis and drug resistance, preventing tumor devel-
opment in vivo.24 However, it is unclear if these mutations 
may affect tumor relapse. Here, employing two different 
models of cancer vaccination in mice and the EL4 
lymphoma model, we show that elimination of cancer 
cells by antigen- specific CD8+ Tc cells ex vivo and in vivo 
is immunogenic and generates a secondary protective 
immune response against endogenous tumor antigens. 
Importantly, specific mutation of the cell death execu-
tioner caspase-3, although did not affect cell killing and 
elimination of primary tumors completely abrogated the 
generation of protective CD8+ Tc cell response against 
secondary tumor development. This finding indicates 
that ICD induced by CD8+ Tc cells and the generation of 
spread immunity against endogenous tumor antigens rely 
on caspase-3- dependent apoptosis of EL4 cancer cells.
Although we have mainly used a model of tumor 
antigen derived from the LCM virus, gp33 antigen, this 
should not be a major limitation to extrapolate our find-
ings to other immunotherapies, like those employing 
viral infections (oncolytic viruses) and others.34 First, ICD 
induced by Tc cells has been confirmed in vivo using a 
conventional approach consisting of vaccination with 
peptide (gp33) pulsed bone marrow–derived DCs, which 
has been previously shown to offer CTL priming and 
tumor immunity.33 In addition, the affinity of the antigen 
T cell receptor for viral gp33 is similar to that one for 
‘real’ tumor antigens like MelA or gp100.35 36 This affinity 
is even higher for engineered T cell receptors as in CAR- T 
cells. Anyway, we have confirmed that our results are not 
restricted to gp33- antigen since elimination of EL4.OVA 
cells in mice vaccinated with OVA- pulsed bone marrow–
derived DCs significantly delayed the development of 
parental EL4 tumors. Thus, the use of two different surro-
gate antigens supports the conclusion that our results 
are not influenced by the selection of specific surrogate 
tumor antigens. Moreover, a similar result in other tumor 
models employing different tumor antigens has been 
shown by Ignacio Melero’s group in an accompanying 
paper (Cordeiro- Minute et al, to be added in production) 
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Figure 6 Role of caspases and Bcl- xL in the generation of immunity against EL4 antigens. (A) EL4 cells were incubated with 
ex vivo gp33- specific CD8+ T cells from virus- immunized C57BL/6 mice in the presence of the gp33 Ag for 20 hours at an 
effector:target ratio 3:1 (EL4.gp33TcLCMV Group) or at an effector:target ratio 7:1 in the presence of the pan- caspase inhibitor 
Q- VD- OPh (30 µM; EL4.gp33TcLCMV + Q VD group). After this time, cell cultures were collected and used to immunize C57B/L6 
mice via intraperitoneal. At day 0 and day 7, as control, mice were immunized with PBS. On day 14, the different groups were 
inoculated with 2×105 EL4 cells in the right flank. Tumor development was monitored over 25 days as described in the Methods 
section. The data correspond to 12 mice from three independent experiments, where ***p<0.001. Two- way analysis of variance 
(ANOVA) with Bonferroni post- test and log- rank test (Mantel- Cox). (B) The same experiment as in (A) was performed but using 
EL4 cells and the mutants thereof overexpressing Bcl- XL or DNC3. The data correspond to 12 mice from three independent 
experiments, where **p<0.01; ***p<0.001. Two- way ANOVA with Bonferroni post test and log- rank test (Mantel- Cox). (C) wt mice 
were immunized with the indicated gp33- pulsed EL4 dead cells killed as indicated in (A), with PBS (CTR) or with gp33- specific 
Tc cells (TcLCMV). On day 10, splenocytes from these mice were isolated and incubated at an effector:taget ratio 100:1 with EL4 
cells in the absence of the viral peptide gp33. After 18 hours, PS exposure on plasma membrane was measured by three- color 
flow cytometry using Annexin- V. Data are represented as the mean±SD of three independent experiments, using six mice in 
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The concept of immunogenic cell death raised from 
the observation that cancer cells eliminated by specific 
chemotherapy drugs or radiotherapy induced the gener-
ation of protective CD8+ Tc cells against antigens released 
by dying tumor cells.9 10 14 15 20 This response contributed 
to the elimination of the tumor cells and, in addition, it 
was shown to prevent cancer recurrence.9 28 Since then, 
several stimuli have been found to induce ICD on cancer 
cells including irradiation, hyperthermia, infection or 
cell starvation.16 However, and paradoxically, studies 
addressing if cell death induced by CD8+ Tc cells is immu-
nogenic are scarce.
Protection correlates with the generation of well- known 
ICD signals in dying cancer cells: calreticulin membrane 
exposure and the release of HMGB1 and the proinflam-
matory cytokine IL-1β.16 However, several signals have 
been associated to ICD induced by different stimuli. Thus, 
analyzing the effect of in vivo immunization with dead 
cells on tumor development is mandatory to analyze if 
cell death induced by a specific stimulus is immunogenic. 
Here an important question to genuinely identify ICD on 
cancer cells is the potential direct in vivo immunomodu-
latory effects of the stimulus used to kill the cancer cells 
used for the immunization. For example, different drugs, 
commonly referred to as ICD inductors, are capable to 
induce tumor cell death as well as to directly modulate 
the immune system in vivo making it impossible to attri-
bute the observed biological effects solely to ICD, unless 
they are removed before immunization. Activated Tc cells 
also produce several immunomodulatory cytokines that 
might contribute to the effects observed in vivo in our 
study. Having in mind this possibility, our study included 
different controls suggesting that a direct effect of Tc cells 
is not the responsible of the protection observed during 
vaccination with dead EL4 tumor cells. First, inoculation 
of mice with activated Tc cells alone has no effect on 
tumor development. On top of that, immunization with 
the mixture of activated Tc cells and dead tumor cells, 
killed in the absence of caspase-3 activity, did not confer 
any protection against tumor development. An optimal 
approximation would be to separate the cell debris from 
Tc cells after the killing assay. However, this approxima-
tion is challenging and would likely change the immu-
nogeneic properties of cell debris like the presence of 
soluble factors released by dying cells. Thus, being aware 
of this difficult limitation to overcome the in vivo vaccina-
tion experiments strongly support for an immunogeneic 
phenotype of cell death induced by CD8+ Tc cells.
We find herein that general caspase inhibition as well as 
caspase-3 inhibition impairs immunogenicity and spread 
immunity against endogenous tumor antigens. However, 
the role of specific caspases seems to be dependent on 
the stimuli used29 37 38 and likely the tumor cell type. 
Our results show that, at least in EL4 lymphoma cells, 
caspase-3 plays a key role in ICD induced by CD8+ Tc 
cells since vaccination with dying EL4 cells expressing the 
DN caspase-3 mutant does not stimulate the generation 
of CD8+ Tc cells against endogenous EL4 antigens and 
does not protect against secondary tumor development. 
In contrast to caspase-3, the mitochondrial apoptotic 
pathway does not seem to be involved in ICD induced by 
CD8+ Tc cells since Bcl- XL overexpression had no effect.
Further confirming that Tc cells induce ICD in tumor 
cells, we show that the protective effect is loss in mice 
deficient in TLR4 or in BATF3- dependent DCs. TLR4 is 
a receptor for HMGB1, a DAMP that interacts with TLR4 
in DCs for an efficient processing and cross- presentation 
of antigens derived from cells killed by chemotherapy or 
radiotherapy.28 39 Regarding BATF3- dependent cDC1s, 
they are involved in phagocytosis and cross- presentation 
of antigens from dying cells, contributing to protec-
tion against some but not all viral, bacterial and fungal 
infections.31 40 A previous study found out that tumor 
cells killed by OT1- specific Tc cells induced antigen 
cross- presentation by DCs.23 However, that study did not 
analyze whether this killing was immunogenic in the 
tumor context and whether it conferred a protective 
immune response against tumor development. Our data 
show that cancer cells killed by Tc cells bear an ICD that 
promotes cross- presentation by cDC1s, which are specif-
ically required for antitumor immunity following ICD 
induction by Tc cells. These results concur with the essen-
tial role of cDC1s in tumor vaccination41 and its associ-
ation with improved overall survival in several tumors.42 
Indeed, BATF3 is required for an efficient generation of 
Tc cell immunity against primary immunogenic tumors.31 
In addition, BATF3- dependent DCs modulate the efficacy 
of different immunotherapy protocols including adoptive 
T cell therapy or mAb against immune checkpoints.32 42 43 
Our data show the requirement of cDC1 for generation 
of an efficient protective immunity against endogenous 
antigens expressed in dead tumor cells following Tc- in-
duced ICD. Remarkably, cDC1s are not essential for anti-
tumor immunity following other models of ICD.44
As indicated above, our results have been inde-
pendently confirmed using other cancer immunothera-
pies and different tumor models, including transgenic T 
cell receptors and NK cells (Cordeiro- Minute et al, to be 
added in production). Recent findings in clinical trials 
employing T cell- based cancer immunotherapy support 
the novelty, the conceptual advance and the potential 
clinical relevance of our results. It has been recently 
found that during CAR- T cell therapy in gastric cancer, 
new T cell clones against tumor neoantigens are detected 
in patients, a concept known as epitope spreading.45 
Epitope spreading was also observed during cancer vacci-
nation in humans,46 although the molecular basis for this 
phenomena remained unexplored. Our results provide 
an explanation and the molecular mechanism involved in 
that observation, enhancing our mechanistic knowledge 
to design rational new vaccines and other T cell- based 
therapies to overcome antigen loss or the absence of 
known antigens, a problem commonly observed during 
cancer vaccination and CAR- T cell therapy. These new 
protocols may include approaches to overcome potential 
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ConClusIons
Using a mouse in vivo model of cancer immunotherapy, 
we have found that CD8+ Tc cells induce ICD on cancer 
cells, generating spread immunity and a protective Tc 
cell response against endogenous tumor antigens. The 
mechanism involved depends on the presence of active 
caspase-3 and is independent of the mitochondrial cell 
death pathway. These findings indicate that ICD and 
epitope spreading during cell death induced by CD8+ Tc 
cells contribute to the efficacy of cancer immunotherapy. 
Moreover, our findings suggest that mutations in caspase-3 
or in pathways regulating its activity might increase the 
risk of tumor refractoriness and/or recurrence after 
T cell- based cancer immunotherapy. Clinical trials will 
be required to test whether the presence of caspase-3 
mutations and/or inhibitors like XIAP can be used as 
biomarkers to predict relapse during immunotherapy.
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